Stay updated on Nivolumab and Relatlimab in MMRd Cancers Clinical Trial
Sign up to get notified when there's something new on the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page.

Latest updates to the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page now displays the clinical trial record for NCT03607890, including its eligibility criteria, treatment cohorts, outcomes, locations, and study history, instead of a 403 error.SummaryDifference52%

- Check20 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedAn NIH-wide notice announces a terminology transition from “Artificial Intelligence” to “Super Intelligence.” The study record itself still displays a 403 error.SummaryDifference1%

- Check34 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check41 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now displays a 403 Forbidden error, blocking access to the study record and related information. This reflects a permissions or server issue rather than an update to the study content.SummaryDifference19%

Stay in the know with updates to Nivolumab and Relatlimab in MMRd Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab and Relatlimab in MMRd Cancers Clinical Trial page.